IP Library Granted Patent US 10,610,517
Granted Patent B2
US 10,610,517 · App. 14/224,965 · Granted Apr 7, 2020

Compositions and methods for treating neoplastic diseases

Inventors: Kenneth C. Anderson (Wellesley, MA); Dharminder Chauhan (Natick, MA); Michael A. Palladino (Olivenhain, CA)
Assignees: Celgene International II SÀRL; Dana-Farber Cancer Institute, Inc.
A61K31/407A61K31/397A61K31/454A61K31/573A61K31/69A61K31/704A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,610,517
App. No.
14/224,965
Granted
Apr 7, 2020
Kind
B2
Abstract

Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.

Claims (8)

1. A method of treating a neoplastic disease, comprising administering to a patient inflicted with the neoplastic disease: bortezomib; and

a compound of formula (I) or a pharmaceutically acceptable salt thereof:

wherein X is selected from the group consisting of fluorine, chlorine, bromine or iodine;

wherein the neoplastic disease is multiple myeloma; and

wherein the neoplastic disease is sensitive to bortezomib.

2. The method of claim 1 , wherein X is chlorine.

3. The method of claim 1 , wherein the compound of formula (1) has the structure of formula (II):

4. The method of claim 1 , wherein the patient is a human.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2020
From: CELGENE TRI A HOLDINGS LTD.
To: CELGENE INTERNATIONAL II SARL
Reel/Frame 051741/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2020
From: ANDERSON, KENNETH C.; CHAUHAN, DHARMINDER
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 051743/0203 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2018
From: 1096271 B.C. UNLIMITED LIABILITY COMPANY
To: CELGENE TRI A HOLDINGS LTD.
Reel/Frame 046047/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2018
From: CELGENE RESEARCH AND DEVELOPMENT I ULC, FORMERLY KNOWN AS TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
To: 1096271 B.C. UNLIMITED LIABILITY COMPANY
Reel/Frame 046047/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2018
From: PALLADINO, MICHAEL A.
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 046029/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2017
From: NEREUS PHARMACEUTICALS, INC.
To: TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
Reel/Frame 041698/0404 →
Continuity (4)
Continuation 12183007 · Jul 30, 2008
Continuation 11293354 · Dec 2, 2005
Provisional Application 60633161 · Dec 3, 2004
Related Publication 20140349965A1 · Nov 27, 2014